Cometriq

Chemical Namecabozantinib
Dosage FormCapsule (oral; 20 mg, 80 mg)
Drug ClassKinase inhibitors
SystemEndocrine
CompanyExelixis
Approval Year2012

Indication

  • For the treatment of patients with progressive, metastatic medullary thyroid cancer
Last updated on 4/10/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Cometriq (cabozantinib) Prescribing Information.2012Exelixis, Inc. Alameda, CA